



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 7/00	A1	(11) International Publication Number: WO 97/11962 (43) International Publication Date: 3 April 1997 (03.04.97)
(21) International Application Number: PCT/US96/14230 (22) International Filing Date: 4 September 1996 (04.09.96) (30) Priority Data: 60/004,633 29 September 1995 (29.09.95) US 08/578,037 26 December 1995 (26.12.95) US (71) Applicants (for all designated States except US): BIOMEASURE, INCORPORATED [US/US]; 27 Maple Street, Milford, MA 01757 (US). THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COY, David, H. [-/US]; 1529 Fourth Street, New Orleans, LA 70130 (US). TAYLOR, John, E. [-/US]; 74 Fiske Mill Road, Upton, MA 01568 (US). (74) Agent: TSAO, Y., Rocky; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CYCLIC PEPTIDE ANALOGS OF SOMATOSTATIN (57) Abstract A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

CYCLIC PEPTIDE ANALOGS OF SOMATOSTATINBackground of the Invention


Native somatostatin is comprised of both a 14-
5 amino acid isoform (somatostatin-14) and a 18-amino acid
isoform (somatostatin-28). Heiman, et al.,
Neuroendocrinology, 45:429-436 (1987). Because of the
short half-life of the native somatostatin, various
somatostatin analogs have been developed, e.g., for the
10 treatment of acromegaly. Raynor, et al., Molecular
Pharmacol. 43:838 (1993). Five distinct somatostatin
receptors have been identified and characterized. Hoyer,
et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 350:441
(1994). Somatostatin produces a variety of effects,
15 including modulation of hormone release, e.g., growth
hormone, glucagon, insulin, amylin, and neurotransmitter
release. Some of these effects have been associated with
its binding to a specific somatostatin receptor. For
example, the inhibition of growth hormone has been
20 attributed to the somatostatin type-2 receptor ("SSTR-2")
(Raynor, et al., Molecular Pharmacol. 43:838 (1993);
Lloyd, et al., Am. J. Physiol. 268:G102 (1995)) while the
inhibition of insulin has been attributed to the
somatostatin type-5 receptor ("SSTR-5") (Coy, et al.
25 197:366-371 (1993)). It is preferred to have an analog
which is selective for the specific somatostatin receptor
subtype responsible for the desired biological response,
thus, reducing interaction with other receptor subtypes
which could lead to undesirable side effects.

30

Summary of the Invention

The invention relates to a peptide covered by the
following generic formula:

- 2 -



in which

- A_1 is the D- or L-isomer of Cys, or Mpa;
 A_2 is Asn, Gln, an aliphatic amino acid, an aromatic amino acid, or deleted;
 10 A_3 is an aromatic amino acid;
 A_4 is His or an aromatic amino acid;
 A_7 is Thr, Ser, or an aliphatic amino acid;
 A_8 is an aromatic amino acid;
 A_9 is the D- or L-isomer of Cys;
 15 each of R_1 and R_2 is, independently, H, C_{1-12} alkyl, C_{7-20} phenylalkyl, C_{11-20} naphthylalkyl, C_{1-12} hydroxyalkyl, C_{7-20} hydroxyphenylalkyl, C_{11-20} hydroxynaphthylalkyl, or COE_1 where E_1 is C_{1-12} alkyl, C_{7-20} phenylalkyl, C_{11-20} naphthylalkyl, C_{1-12} hydroxyalkyl,
 20 C_{7-20} hydroxyphenylalkyl, or C_{11-20} hydroxynaphthylalkyl; and

- R_3 is NH_2 or $NH \cdot Y \cdot CH_2 \cdot Z$ where Y is a C_{1-12} hydrocarbon moiety (divalent, e.g., straight or branched alkyl group) and Z is H, OH, CO_2H , or $CONH_2$; and
 25 a disulfide bond links the side chains of residues A_1 and A_9 ; or a pharmaceutically acceptable salt thereof.

- In one embodiment, each of A_3 and A_8 , independently, is Phe, p-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), o-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), pyridyl-Ala, Trp, β -Nal, 2,4-dichloro-Phe, Tyr(I), or F₅-Phe, A_4 is His, Phe, p-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), o-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), pyridyl-Ala, Trp, β -
 30 Nal, 2,4-dichloro-Phe, Tyr(I), or F₅-Phe, A_2 is Asn, Gln, Ala, Aib, Val, Leu, Ile, Nle, Nva, Abu, Phe, p-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), o-X-Phe (where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), pyridyl-

- 3 -

Ala, Trp, β -Nal, 2,4-dichloro-Phe, Tyr(I), F₅-Phe, or is deleted, and A₇ is Thr, Ser, Ala, Aib, Val, Leu, Ile, Nle, Nva, or Abu.

In a further embodiment, A₉ is Cys, each of A₃ and
 5 A₈, independently, is Phe, p-X-Phe (where X is a halogen, OH, or CH₃), Tyr(I), or Trp, A₄ is His, Phe, p-X-Phe (where X is a halogen, OH, or CH₃), Tyr(I), or Trp, A₂ is Asn, Gln, or is deleted, and A₇ is Thr or Ser.

In a still further embodiment, A₂ is Asn or is
 10 deleted, A₃ is Phe, A₄ is Phe, His, p-X-Phe (where X is a halogen, OH, or CH₃), Tyr(I), or Trp, A₈ is Phe or p-X-Phe (where X is a halogen, OH, or CH₃), and each of R₁ and R₂, independently, is H, and R₃ is NH₂.

Below are examples of the peptides of this
 15 invention as covered by the above formula:

H₂-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH₂
 (Analog I),

H₂-c[D-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH₂
 (Analog II),

20 H₂-c[Cys-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH₂,
 H₂-c[D-Cys-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH₂,
 H₂-c[Cys-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH₂,
 H₂-c[D-Cys-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH₂,
 H₂-c[Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH₂

25 (Analog IV),
 H₂-c[D-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH₂,
 H₂-c[Cys-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys]-NH₂
 (Analog III),

H₂-c[D-Cys-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys]-NH₂,
 30 H₂-c[Cys-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH₂,
 H₂-c[D-Cys-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH₂,
 H₂-c[Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH₂
 (Analog VIII),

H₂-c[D-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH₂,
 35 H₂-c[Cys-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys]-NH₂,
 H₂-c[D-Cys-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys]-NH₂,

- 4 -

- $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 (Analog V),
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$,
 5 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-His-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-His-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 10 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-His-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-His-D-Trp-Lys-Ser-Phe-Cys}]\text{-NH}_2$,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys}]\text{-}$
 15 NH_2 ,
 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys}]\text{-}$
 NH_2 ,
 $\text{H}_2\text{-c}[\text{Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys}]\text{-}$
 NH_2 ,
 20 $\text{H}_2\text{-c}[\text{D-Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys}]\text{-}$
 NH_2 ,
 $\text{H}_2\text{-c}[\text{Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 (Analog VI),
 $\text{H}_2\text{-c}[\text{Cys-Phe-}\delta\text{-Nal-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 25 (Analog VII),
 $\text{H}_2\text{-c}[\text{Cys-Phe-Cpa-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 (Analog IX),
 $\text{H}_2\text{-c}[\text{Mpa-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 (Analog X),
 30 $\text{H}_2\text{-c}[\text{Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-D-Cys}]\text{-NH}_2$
 (Analog XI),
 $\text{H}_2\text{-c}[\text{Cys-Phe-Phe-D-Trp-Lys-Thr-Tyr-Cys}]\text{-NH}_2$
 (Analog XII),
 $\text{H}_2\text{-c}[\text{Cys-Phe-His-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$
 35 (Analog XIII),

- 5 -

With the exception of the N-terminal amino acid, all abbreviations (e.g., Ala or A₂) of amino acids in this disclosure stand for the structure of -NH-CH(R)-CO-, wherein R is a side chain of an amino acid (e.g., CH₃ for Ala). For the N-terminal amino acid, the abbreviation stands for =N-CH(CH₂SH)-CO- if it is the D- or L-isomer of Cys or =C(-CH₂SH)-CO- if it is the D- or L-isomer of Mpa, wherein R is a side chain of an amino acid. Nle, Nva, pyridyl-Ala, F₅-Phe, 2,4-dichloro-Phe, β-Nal, Abu, Mpa, Cpa, and Aib are respective abbreviations of the following α-amino acids: norleucine, norvaline, β-pyridyl-alanine, pentafluoro-phenylalanine, 2,4-dichlorophenylalanine, β-naphthylalanine, α-aminobutyric acid, mercaptopropionic acid, p-chlorophenylalanine, and α-aminoisobutyric acid. Tyr(I) refers to an iodinated tyrosine residue (e.g., 3-I-Tyr, 5-I-Tyr, 3,5-I-Tyr) wherein the iodine may be a radioactive isotope, e.g., I¹²⁵, I¹²⁷, or I¹³¹. An aliphatic amino acid is an α-amino acid having one or two side chains which, independently, are hydrocarbons, e.g., a straight or branched chain of 1-6 carbons. Examples of aliphatic amino acids include Ala, Aib, Val, Leu, Ile, Nle, Nva, or Abu. An aromatic amino acid is an α-amino acid the side chain of which has a neutral (e.g., not acidic or basic) aromatic substituent, e.g., a substituted or unsubstituted phenyl, naphthyl, or aromatic heterocycle group (e.g., pyridyl or indolyl). Examples of aromatic amino acids include Phe, p-X-Phe (where X is a halogen (e.g., F, Cl, or I), OH, OCH₃, CH₃, or NO₂), o-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), pyridyl-Ala, Trp, β-Nal, 2,4-dichloro-Phe, Tyr(I), F₅-Phe. Where the amino acid residue is optically active, it is the L-isomer that is intended unless otherwise specified. Also, in the above generic formula, hydroxyalkyl, hydroxyphenylalkyl, and hydroxynaphthylalkyl may contain 1-4 hydroxy substituents, and COE₁ stands for -C=O·E₁. Examples of

- 6 -

-C=O·E₁ include, but are not limited to, p-hydroxy-phenylpropionyl (i.e., -C=O·CH₂-CH₂-C₆H₄-OH) and phenylpropionyl. In the formula set forth herein, the disulfide bond between the thiol group on the side chain of residue A₁ (e.g., Mpa, D-Mpa, Cys, or D-Cys) and the thiol group on the side chain of residue A₉ (e.g., Mpa, D-Mpa, Cys, or D-Cys) is not shown. A peptide of this invention is also denoted herein by another format, e.g., H₂-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH₂, with the two disulfide bonded residues (i.e., Cys) placed between the two brackets following "c".

The peptides of the invention can be used to inhibit the release of insulin in a subject (a mammal such as a human patient). Thus, the peptides are useful in the treatment of physiological conditions in which the inhibition of the release of insulin is of benefit, e.g., type II diabetes. Also, peptides of the invention having a Tyr(I) residue can be used to image cells containing somatostatin receptors (e.g., SSTR-5). Such peptides of the invention can be used either *in vivo* to detect cells having somatostatin receptors (e.g., cancer cells) or *in vitro* as a radioligand in a somatostatin receptor binding assay.

The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).

A therapeutically effective amount of a peptide of this invention and a pharmaceutically acceptable carrier substance (e.g., magnesium carbonate, lactose, or a phospholipid with which the therapeutic compound can

- 7 -

form a micelle) together form a therapeutic composition (e.g., a pill, tablet, capsule, or liquid) for administration (e.g., orally, intravenously, transdermally, pulmonarily, vaginally, subcutaneously, 5 nasally, iontophoretically, or by intratracheally) to a subject in need of the peptide. The pill, tablet, or capsule can be coated with a substance capable of protecting the composition from the gastric acid or intestinal enzymes in the subject's stomach for a period 10 of time sufficient to allow the composition to pass undigested into the subject's small intestine. The therapeutic composition can also be in the form of a biodegradable or nonbiodegradable sustained release formulation for subcutaneous or intramuscular 15 administration. See, e.g., U.S. Patents 3,773,919 and 4,767,628 and PCT Application No. WO 94/00148. Continuous administration can also be obtained using an implantable or external pump (e.g., INFUSAID™ pump) to administer the therapeutic composition. The peptide can 20 be administered prior to bedtime of the patient.

The dose of a peptide of the present invention for treating the above-mentioned diseases or disorders varies depending upon the manner of administration, the age and the body weight of the subject, and the condition 25 of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such an amount of the peptide as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount."

30 Also contemplated within the scope of this invention is a peptide covered by the above generic formula for both use in treating diseases or disorders associated with the need to inhibit insulin release, e.g., type II diabetes, and use in detecting somatostatin 35 receptors, e.g., radioimaging.

- 8 -

Other features and advantages of the present invention will be apparent from the detailed description and from the claims.

Detailed Description of the Invention

5 The synthesis and use of somatostatin analogs of this invention are well within the ability of a person of ordinary skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill
10 in the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.

It is believed that one skilled in the art can,
15 based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

20 Synthesis of Somatostatin Analogs

The synthesis of short peptides is well examined in the peptide art. See e.g., Stewart, et al., Solid Phase Peptide Synthesis (Pierce Chemical Co., 2d ed., 1984). The following is the synthesis of Analog I.
25 Other peptides of the invention can be prepared in an analogous manner by a person of ordinary skill in the art.

Benzyldrylamine-polystyrene resin (Advanced ChemTech, Inc., Louisville, KY) (1.1 g, 0.5 mmole) in the
30 chloride ion form was placed in the reaction vessel of an Advanced ChemTech ACT 200 peptide synthesizer programmed to deliver the following reagents/solvents: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 25 min each); (c) methylene

- 9 -

chloride; (d) ethanol; (e) methylene chloride; and (f) 10% triethylamine in chloroform.

The neutralized resin was stirred with Boc-S-4-methylbenzyl-Cys and diisopropylcarbodiimide (1.5 mmole each) in methylene chloride for 1 h and the resulting amino acid resin was then cycled through steps (a) to (f) in the above wash program. The following amino acids (1.5 mmole) were then coupled successively by the same procedure: Boc-Phe, Boc-O-benzyl-Thr, Boc-N-benzyloxycarbonyl-Lys, Boc-D-Trp, Boc-Phe, Boc-Phe, and Boc-S-methylbenzyl-Cys. After washing and drying, the completed resin weighed 1.6 g.

The resin (1.6 g, 0.5 mmole) was then mixed with anisole (5 ml), dithiothreitol (100 mg), and anhydrous hydrogen fluoride (35 ml) at 0°C and stirred for 45 min. Excess hydrogen fluoride was evaporated rapidly under a stream of dry nitrogen, and the free peptide precipitated and washed with ether. The crude peptide was then dissolved in 500 ml of 90% acetic acid to which was added a concentrated solution of I₂/MeOH until a permanent brown color was observed. Excess I₂ was removed by addition of ascorbic acid, and the solution evaporated to a small volume which was applied to a column (2.5 x 90 cm) of SEPHADEX™ G-25 which was eluted with 50% ACOH. Fractions containing a major component by ultraviolet (UV) absorption and thin layer chromatography were then pooled, evaporated to a small volume, and applied to a column (1.5 x 70 cm) of VYDAC™ octadecylsilane silica (10-15 μm). This column was eluted with a linear gradient from 80 percent A and 20 percent B to 40 percent A and 60 percent B where A is 0.1% trifluoroacetic acid (TFA) in water and B is 79.9% acetonitrile, 20% water, and 0.1% TFA. Fractions were examined by thin layer chromatography (tlc) and analytical high performance liquid chromatography (hplc) and pooled to give maximum purity. Repeated lyophilization of the solution from

- 10 -

water gave 95 mg of the product as a white, fluffy powder.

The product is found to be homogenous by hplc and tlc. Amino acid analysis of an acid hydrolysate and
5 matrix-assisted laser desorption mass spectrometry (MALDI MS) confirmed the composition of the cyclic octapeptide (MW calculated, 1077; MW found, 1080).

The following is the synthesis of Analog V.
Benzylhydramine-polystyrene resin (Advanced ChemTech,
10 Inc.) (0.7 g, 0.25 mmole) in the chloride ion form was placed in the reaction vessel of an Advanced ChemTech ACT 200 peptide synthesizer programmed to deliver the following reagents/solvents: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times
15 for 1 and 25 min each); (c) methylene chloride; (d) ethanol; (e) methylene chloride; and (f) 10% triethylamine in chloroform.

The neutralized resin was stirred with Boc-S-methylbenzyl-Cys and diisopropylcarbodiimide (1.5 mmole
20 each) in methylene chloride for 1 h and the resulting amino acid resin was then cycled through steps (a) to (g) in the above wash program. The following amino acids (1.5 mmole) were then coupled successively by the same procedure: Boc-Phe, Boc-O-benzyl-Thr, Boc-N-
25 benzyloxycarbonyl-Lys, Boc-D-Trp, Boc-Phe, Boc-Phe, Boc-Asn, and Boc-S-methylbenzyl-Cys. After washing and drying, the completed resin weighed 1.2 g. The peptide resin was subjected to HF cleavage and I₂ cyclization as described above. Column purification, as described
30 above, yielded 21 mg of the cyclic nonapeptide which was found to be homogeneous by hplc and tlc. Amino acid analysis of an acid hydrolysate and MALDI MS confirmed the composition of the cyclic nonapeptide (MW calculated, 1192; found, 1192).

35 The synthesis of iodinated somatostatin analogs at the tyrosine residue (e.g., the chloramine-T method) is well documented and are within the ability of a person

- 11 -

of ordinary skill in the art. See, e.g., Czernick, et al., J. Biol. Chem. 258:5525 (1993) and European Patent No. 389,180 B1.

5 Somatostatin Receptor Binding Assay

(1) Human SSTR-2 Binding Assay:

CHO-K1 (ovary, Chinese hamster) cells were obtained from the American Type Culture Collection (ATCC) (Rockville, MD) (ATCC No. CCL61) and were
10 transfected with the human SSTR-2 cDNA, described in Yamada, et al., Proc. Natl. Acad. Sci. USA, 89:251-255 (1992) and also available from ATCC (ATCC No. 79046), using standard techniques known in the molecular biological art. See, e.g., Patel, et al., Biochem.
15 Biophys. Res. Commun. 198:605 (1994). Crude membranes were prepared by homogenizing the human SSTR-2 transfected CHO-K1 cells in 20 ml of ice-cold 50 mM Tris-HCl (Buffer A) with a POLYTRON[™] homogenizer (Brinkmann Instruments, Westbury, NY) at setting 6, for 15 sec.
20 Additional Buffer A was added to obtain a final volume of 40 ml, and the homogenate was centrifuged in a SORVAL[™] SS-34 rotor (DuPont, Newtown, CT) at 39,000 g for 10 min at 0-4°C. The resulting supernatant was decanted and discarded. The pellet was rehomogenized in ice-cold
25 Buffer A, diluted, and centrifuged as before. The final pellet was resuspended in the 10 mM Tris HCl and held on ice for the receptor binding assay.

Aliquots of the membrane preparation were incubated for 90 min at 25°C with 0.05 nM [¹²⁵I-Tyr]MK-678
30 (2000 Ci/mmol; c[N-methyl-Ala-Tyr(I¹²⁵)-D-Trp-Lys-Val-Phe]) in 50 mM HEPES (pH 7.4) containing a test peptide at various concentrations (e.g., 10⁻¹¹ to 10⁻⁶ M), 10 mg/ml bovine serum albumin (fraction V, Sigma Chemical Co., St. Louis, MO), MgCl₂ (5 mM), Trasylol (200 KIU/ml),
35 bacitracin (0.02 mg/ml), and phenylmethyl-sulphonyl fluoride (0.02 mg/ml). The final assay volume was 0.3 ml. The incubations were terminated by rapid filtration

- 12 -

through GF/C filters (pre-soaked in 0.3% polyethylenimine for 30 min) using a filtration manifold (Brandel, Gaithersburg, MD). Each tube and filter was then washed three times with 5 ml aliquots of ice-cold Buffer A.

- 5 Specific binding was defined as the total [^{125}I -Tyr]MK-678 bound minus that bound in the presence of 200 nM somatostatin-14.

The following test peptides were assayed:

- somatostatin-14, somatostatin-28, Analog I, Analog II,
10 Analog III, Analog IV, and Analog V. The structure of Analogs I-V are shown above. The K_i values for the test peptides were calculated by using the following formula:

- $K_i = \text{IC}_{50} / [1 + (\text{LC}/\text{LEC})]$ where IC_{50} is the concentration of the test peptide required to inhibit 50 percent of the
15 specific binding of the radioligand [^{125}I -Tyr]MK-678, LC is the concentration of the radioligand (0.05 nM), and LEC is the equilibrium dissociation constant of the radioligand (0.155 nM). The K_i values calculated for the test peptides are shown in the column under the heading
20 "SSTR-2" in Table I.

(2) Human SSTR-5 Binding Assay

- CHO-K1 cells were transfected with the human SSTR-5 cDNA, described in Yamada, et al., Biochem
25 Biophys. Res. Commun., 195-844 (1993) using standard techniques known in the molecular biological art. See, e.g., Patel, et al., Biochem. Biophys. Res. Comm. 198:605 (1994). Crude membranes were prepared by homogenization of the human SSTR-5 transfected CHO-K1 cells in 20 ml of
30 ice-cold 50 mM Tris-HCl with a POLYTRON[™] homogenizer (setting 6, 15 sec). Buffer was added to obtain a final volume of 40 ml, and the homogenate was centrifuged in a SORVAL[™] SS-34 rotor at 39,000 g for 10 min at 0-4°C. The resulting supernatant was decanted and discarded. The
35 pellet was rehomogenized in ice-cold buffer, diluted, and

- 13 -

centrifuged as before. The final pellet was resuspended in the 10 mM Tris HCl and held on ice for the receptor binding assay.

Aliquots of the membrane preparation were
5 incubated for 30 min at 30°C with 0.05 nM [¹²⁵I-Tyr¹¹]somatostatin-14 (2000 Ci/mmol; Amersham Corp.,
Arlington Heights, IL) in 50 mM HEPES (pH 7.4) containing
a test peptide at various concentrations (e.g., 10⁻¹¹ to
10⁻⁶ M), 10 mg/ml bovine serum albumin (fraction V), MgCl₂
10 (5 mM), Trasylol (200 KIU/ml), bacitracin (0.02 mg/ml),
and phenylmethyl-sulphonyl fluoride (0.02 mg/ml). The
final assay volume was 0.3 ml. The incubations were
terminated by rapid filtration through GF/C filters (pre-
soaked in 0.3% polyethylenimine for 30 min) using a
15 Brandel filtration manifold. Each tube and filter was
then washed three times with 5 ml aliquots of ice-cold
buffer. Specific binding was defined as the total [¹²⁵I-Tyr¹¹]somatostatin-14 bound minus that bound in the
presence of 1000 nM of the somatostatin type-5 receptor
20 ligand BIM-23052 (H₂-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂). The K_i values for the test peptides were calculated
by using the following formula: IC₅₀/[1+(LC/LEC)] where
IC₅₀ is the concentration of the test peptide required to
inhibit 50 percent of the specific binding of the
25 radioligand [¹²⁵I-Tyr¹¹]somatostatin-14, LC is the
concentration of the radioligand (0.05 nM), and LEC is
the equilibrium dissociation constant of the radioligand
(0.16 nM). The K_i values calculated for the test
peptides are shown in the column under the heading "SSTR-
30 5" in Table I.

Table I also shows the respective ratios of the
K_i's for the human SSTR-2 and the K_i's for the human SSTR-
5. The peptides of the invention (e.g., Analogs I-V)
have ratios unexpectedly greater than one and, thus, are
35 more selective for the SSTR-5 than for the SSTR-2.

- 14 -

TABLE 1

	COMPOUND	SSTR-2	SSTR-5	SSTR-2/SSTR-5
	Somatostatin-14	0.187	0.883	0.212
	Somatostatin-28	0.242	0.383	0.632
5	Analog I	15.1	0.376	40.2
	Analog II	13.0	2.63	4.94
	Analog III	14.7	1.21	12.1
	Analog IV	19.3	0.928	20.8
	Analog V	129	2.43	53.1
10	Analog VI	6.19	0.34	18.2
	Analog VII	8.07	4.145	1.94
	Analog VIII	4.78	0.27	17.7
	Analog IX	6.205	4.77	1.30
	Analog X	15.0	0.744	20.1
15	Analog XI	34.83	28.04	1.24
	Analog XII	59.20	5.78	10.2
	Analog XIII	32.32	2.01	16.1

Other Embodiments


It is to be understood that while the invention
 20 has been described in conjunction with the detailed
 description thereof, that the foregoing description is
 intended to illustrate and not limit the scope of the
 invention, which is defined by the scope of the appended
 claims. Other aspects, advantages, and modifications are
 25 within the claims.

What is claimed is:

- 15 -

CLAIMS

1. A peptide of the formula:



in which


- A_1 is the D- or L-isomer of Cys or Mpa;
 10 A_2 is Asn, Gln, an aliphatic amino acid, an aromatic amino acid, or deleted;
 A_3 is an aromatic amino acid;
 A_4 is His or an aromatic amino acid;
 A_7 is Thr, Ser, or an aliphatic amino acid;
 15 A_8 is an aromatic amino acid;
 A_9 is the D- or L-isomer of Cys;
 each of R_1 and R_2 is, independently, H, C_{1-12} alkyl, C_{7-20} phenylalkyl, C_{11-20} naphthylalkyl, C_{1-12} hydroxyalkyl, C_{7-20} hydroxyphenylalkyl, C_{11-20} hydroxynaphthylalkyl, or COE_1 where E_1 is C_{1-12} alkyl, C_{7-20} phenylalkyl, C_{11-20} naphthylalkyl, C_{1-12} hydroxyalkyl, C_{7-20} hydroxyphenylalkyl, or C_{11-20} hydroxynaphthylalkyl;
 20 and
 R_3 is NH_2 or $NH \cdot Y \cdot CH_2 \cdot Z$ where Y is a C_{1-12} hydrocarbon moiety and Z is H, OH, CO_2H , or $CONH_2$; and
 25 a disulfide bond links the side chains of residues A_1 and A_9 ; or a pharmaceutically acceptable salt thereof.

- 16 -


2. A peptide of claim 1, wherein each of A₃ and A₈, independently, is Phe, p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), o-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), pyridyl-Ala, Trp, β -Nal, 2,4-dichloro-Phe, Tyr(I), or F₅-Phe, and A₄ is His, Phe, p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), o-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), pyridyl-Ala, Trp, β -Nal, 2,4-dichloro-Phe, Tyr(I), or F₅-Phe.
3. A peptide of claim 2, wherein A₂ is deleted, and A₇ is Thr, Ser, Ala, Aib, Val, Leu, Ile, Nle, Nva, or Abu.
4. A peptide of claim 3, wherein A₉ is Cys.
5. A peptide of claim 4, wherein each of A₃ and A₈, independently, is Phe, p-X-Phe (where X is a halogen, OH, or CH₃), Tyr(I), or Trp, and A₄ is His, Phe, p-X-Phe (where X is a halogen, OH, or CH₃), Tyr(I), or Trp.
6. A peptide of claim 5, wherein A₇ is Thr or Ser.
7. A peptide of claim 6, wherein A₃ is Phe, A₄ is Phe, p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), His, Tyr(I), or Trp, and A₈ is Phe or p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂).
8. A peptide of claim 6, wherein A₃ is Phe, A₄ is Phe, Tyr, Tyr(I), or Trp, and A₈ is Phe.
9. A peptide of claim 8, wherein each of R₁ and R₂, independently, is H, and R₃ is NH₂.

- 17 -

10. A peptide of claim 9 of the formula:



11. A peptide of claim 7 of the formula:



12. A peptide of claim 2, wherein A_2 is Asn,
20 Gln, Ala, Aib, Val, Leu, Ile, Nle, Nva, Abu, Phe, p-X-Phe
(where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), o-X-Phe
(where X is a halogen, OH, OCH_3 , CH_3 , or NO_2), pyridyl-
Ala, Trp, β -Nal, 2,4-dichloro-Phe, Tyr(I), or F_5 -Phe, and
 A_7 is Thr, Ser, Ala, Aib, Val, Leu, Ile, Nle, Nva, or
25 Abu.

13. A peptide of claim 12, wherein A_9 is Cys.

14. A peptide of claim 13, wherein each of A_3 ,
 A_4 , and A_8 , independently, is Phe, p-X-Phe (where X is a
halogen, OH, or CH_3), Tyr(I), or Trp, and A_4 is His, Phe,
30 p-X-Phe (where X is a halogen, OH, or CH_3), Tyr(I) or
Trp.

- 18 -


15. A peptide of claim 14, wherein A₂ is Asn or Gln, and A₇ is Thr or Ser.

16. A peptide of claim 15, wherein A₃ is Phe, A₄ is Phe, p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂), His, Tyr(I), or Trp, and A₈ is Phe or p-X-Phe (where X is a halogen, OH, OCH₃, CH₃, or NO₂).


17. A peptide of claim 16, wherein A₃ is Phe, A₄ is Phe, Tyr, Tyr(I), or Trp, and A₈ is Phe.

18. A peptide of claim 17, wherein A₂ is Asn, each of R₁ and R₂, independently, is H, and R₃ is NH₂.

19. A peptide of claim 18 of the formula:



20. A peptide of claim 16 of the formula:



- 19 -

21. A peptide of claim 1 of the formula:
 $\text{H}_2\text{-c}[\text{Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys}]\text{-NH}_2$.

INTERNATIONAL SEARCH REPORT

Int. .tional application No.
PCT/US96/14230

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 7/00

US CL :530/311

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/311, 328

930/160

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

somatostatin, cyclic, analog, nonapeptide, octapeptide, cys-phe-phe-d-trp-lys-thr-phe-cys

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,798,821 (HARTMANN) 17 January 1989, column 2, structure (IV); column 1, line 40 to column 3 line 10.	1-14, 21
Y	US, A, 5,358,934 (BOROVSKY et al.) 25 October 1994, column 2, line 64 to column 3 line 2.	1-14, 21
Y	EP, A, 0021585 (AMERICAN HOME PRODUCTS CORP) 07 January 1981, page 2, lines 6-9.	1-14, 21
Y	AU 84721/91 B (SANDOZ LTD) 21 November 1991, page 26, line 27.	1-14, 21
Y	BE 900089-A (SANDOZ S.A.) 07 January 1985, page 13, line 18.	1-14, 21

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 OCTOBER 1996

Date of mailing of the international search report

04 NOV 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CYBILLE DELACROIX-MUIRHEID

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

Int'l application No.

PCT/US96/14230

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	FR 2523125, 16 September 1983, pages 21 and 22, claims 6 and 7 respectively.	1,2,12,13 14 ----- 1-14, 21

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.